Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

While the TrumpRx deals only cover Lilly and Novo for now, the agreements are good for any cardiometabolic biotechs waiting in the wings, according to a new 2026 preview report from PitchBook.

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.